Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Evidence For Cannabidiol Modulation of Serotonergic Transmission in a Model of Osteoarthritis via <i>in vivo</i> PET Imaging and Behavioral Assessment.

International journal of innovative research in medical science·2023
Same author

RS12574989 and haplotype associated with α/β-chain imbalance and population HbA2 reduction.

BMC medical genomics·2022
Same author

Cooperative ETM-Based Adaptive Neural Network Tracking Control for Nonlinear Pure-Feedback MASs: A Special-Shaped Laplacian Matrix Method.

IEEE transactions on neural networks and learning systems·2022
Same author

Effect of femoral head necrosis cystic area on femoral head collapse and stress distribution in femoral head: A clinical and finite element study.

Open medicine (Warsaw, Poland)·2022
Same author

Novel optimal trajectory tracking for nonlinear affine systems with an advanced critic learning structure.

Neural networks : the official journal of the International Neural Network Society·2022

Related Experiment Video

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Drug Development.

Fernando Goni1, Ding Wang1, Jianina Suazo1

  • 1NYU Grossman School of Medicine, New York, NY, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary

Two IgM antibodies targeting amyloid-beta oligomers, GW-23B7 and WG-3D7, demonstrated significant cognitive rescue in Alzheimer's disease (AD) mouse models. These AβComAbs reduced Aβ pathology without causing inflammation or microhemorrhages, suggesting potential for safe human clinical trials.

More Related Videos

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Related Experiment Videos

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Area of Science:

  • Neuroscience
  • Immunology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) pathology involves amyloid-beta (Aβ) oligomers with specific β-sheet secondary structures.
  • Previous studies showed an IgM monoclonal antibody (GW-23B7) targeting these structures rescued cognition in AD mouse models without adverse effects.
  • This study investigates two such antibodies, GW-23B7 and WG-3D7, in a cerebral amyloid angiopathy (CAA) model with varying human apolipoprotein E (apoE) allotypes.

Purpose of the Study:

  • To evaluate the therapeutic efficacy and safety of two Aβ oligomer-targeting IgM antibodies (GW-23B7 and WG-3D7).
  • To assess antibody performance in a transgenic mouse model of cerebral amyloid angiopathy (CAA) expressing human apoE isoforms (E2, E3, E4).
  • To determine if these antibodies reduce Aβ pathology and improve cognitive function without inducing adverse effects like inflammation or microhemorrhages.

Main Methods:

  • Preclinical trial involving 11-month-old TgSwDI mice (with apoE2, E3, or E4) treated weekly for two months with GW-23B7 or WG-3D7 (100 µg/animal).
  • Behavioral and cognitive testing (e.g., Barnes Maze) and locomotor assessments were performed.
  • Brain tissue analysis included immunohistochemistry (Iba1, GFAP, CD-45) and biochemical assays (ELISA) to quantify Aβ pathology and glial activation.

Main Results:

  • Both GW-23B7 and WG-3D7 penetrated the blood-brain barrier (BBB) and interacted with brain vasculature without causing microhemorrhages (Prussian Blue staining).
  • Treated mice showed significant cognitive improvement compared to controls, correlating with reduced soluble aggregated Aβ and decreased vascular/parenchymal Aβ deposition.
  • Immunohistochemistry revealed a reduction in activated glia (Iba1, GFAP, CD-45) in treated groups; minor differences were observed between the two antibodies.

Conclusions:

  • Peripherally administered Aβ oligomer-targeting IgM antibodies (GW-23B7, WG-3D7) effectively reduce soluble and deposited Aβ pathology via an Aβ-sequence independent mechanism.
  • These antibodies avoid Antibody-Dependent Cell-mediated Cytotoxicity (ADCC)-induced microhemorrhages or inflammation, regardless of human apoE allotype.
  • Preclinical data support the safe translation of these IgM antibodies into human AD clinical trials with a low risk of ARIA or autoimmune complications.